Your session is about to expire
← Back to Search
7 mg/Mn/kg for Brain Tumor
Study Summary
This trial will test the safety, effectiveness, and how the drug moves through the body of a new medication called RVP 001. It will be given to patients with specific brain lesions through an IV
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 trial • 32 Patients • NCT05413668Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are new participants currently being welcomed to enroll in this trial?
"Indeed, the details on clinicaltrials.gov indicate that this trial is presently seeking participants. Its posting date was 4/1/2024, with the most recent update recorded as 3/18/2024. The study aims to enroll a total of 24 individuals distributed among 3 locations."
Are individuals older than 45 years eligible to participate in this study?
"This clinical investigation is open to individuals aged 18 and older but under the age of 65."
Has the FDA granted approval for a dosage of 7 milligrams per square meter per kilogram?
"The safety evaluation of 7 mg/Mn/kg is rated at 2 by our team due to the ongoing Phase 2 trial, indicating some existing safety data but lacking evidence for efficacy."
Share this study with friends
Copy Link
Messenger